POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Otsuka Icu Medcl	POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER	dextrose; potassium chloride	INJECTABLE;INJECTION	018371	NDA	ICU Medical Inc.	0990-7905-09	12 POUCH in 1 CASE (0990-7905-09) / 1 BAG in 1 POUCH / 1000 mL in 1 BAG	2020-11-20
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: May 18, 2026

Potassium Chloride 20 mEq in Dextrose 5% (KCl 20 mEq/ D5W) Plastic Container: Who Supplies It, Where Is It Sold, and What to Buy for Distribution

This product is a combination IV solution supply category: potassium chloride added to dextrose 5% in water, packaged in a plastic container, typically as an IV bag (commonly 100 mL, 150 mL, or 250 mL configurations depending on label). Supply is fragmented across global IV bag manufacturers and regional pharmaceutical product packagers. To avoid procurement risk, buyers generally source through (1) the product’s labeled marketing authorization holder (MAH) and their distributors, (2) IV admixture contract manufacturers where available, or (3) wholesale channels for the exact NDC/strength/container size.

What follows is the supplier set by supply channel and practical procurement target, not a speculative list of “companies that might sell it.” If you need a strict “named manufacturer of the finished labeled product for a specific NDC and container size,” that can only be done from the exact market label identifiers.

Who manufactures potassium chloride in dextrose 5% IV bags (plastic container) by market?

U.S. supply: product typically distributed under NDC with MAH/distributor

In the U.S., KCl added to D5W in plastic is typically supplied as a pre-mixed, labeled IV solution under an NDC by a branded generic MAH and distributed via wholesalers and hospital distributors. Procurement normally follows one of three patterns:

MAH + wholesale distribution
- Buyer purchases the exact NDC from contract distributors and GPOs.
- Label package (plastic bag), concentration, and container size are controlled by the NDC.
Hospital IV procurement via group purchasing organizations
- Hospitals buy through GPO-negotiated SKUs.
- The “supplier” is the GPO contract holder for that NDC.
Contract admixture
- Less common for this exact “20 mEq in D5W” presentation if the market is dominated by ready-to-use products.
- Used where pre-mixes are not available or for alternative strengths/volumes.

Procurement-critical inputs for supplier selection

To keep SKU-matching tight, procurement usually gates on:

Container type: plastic (commonly flexible IV bag).
KCl strength basis: “20 mEq per bag” presentation.
Solvent: dextrose 5% in water (D5W).
Total volume: must match label (varies by product presentation).
Salt form: potassium chloride.
Sterility and compendial compliance: USP/EP standards as applicable by market.
Labeling and traceability: lot-controlled for IV use.

Which companies supply KCl 20 mEq in D5W 5% IV plastic bags for hospitals?

Supply chain reality

KCl in D5W IV plastic is supplied in practice by a combination of:

Finished-dose IV bag manufacturers and MAHs that own the NDC/label.
Wholesalers and hospital distribution networks that deliver to acute care and long-term care settings.
GPO contract holders that decide pricing and availability.

The supplier you should lock is the MAH/NDC source, not a generic “IV bag supplier,” because manufacturing sites can change while the label stays within an MAH’s control.

Do IV admixture providers supply potassium chloride in dextrose 5% in plastic bags?

When admixture becomes the fallback

Admixture is used when:

The exact 20 mEq in D5% format is not reliably stocked.
Hospitals need surge capacity across multiple strengths/volumes.
Procurement consolidates purchasing with contract pharmacies or sterile compounding networks.

Admixture procurement checkpoints

Buyers typically require:

Sterile compounding documentation (USP <797> compliance).
Controlled process validation for KCl addition into D5W.
Container compatibility validation for plastic bag types used.
Lot traceability for both D5W base and KCl source.

What packaging suppliers (plastic IV bag manufacturers) are used for dextrose 5% + KCl IV solutions?

Key point: bag makers are not always the drug MAH

Plastic container suppliers (the bag and closure system) are often separate from the MAH that manufactures/fills the solution.

Procurement impact:

Drug label and NDC are tied to the MAH.
Bag material and closure configuration can vary across MAHs and change across time.

If the procurement requirement is strictly “plastic container,” the bag system must be reviewed at the NDC/label level.

Where can buyers source KCl 20 mEq in D5W from distributors and GPOs?

High-probability route for procurement

For U.S. hospital buyers, the dominant route is:

GPO catalog listing for the NDC (GPO supplier).
Wholesaler fulfillment (McKesson, Cardinal, AmerisourceBergen, or equivalent regional players depending on contract).
Direct MAH distribution where contracts support it.

This is the practical way to ensure the exact strength and container presentation.

How do you qualify suppliers to reduce recall, compatibility, and shortage risk?

Supplier qualification checklist for this product category

At minimum, hospital procurement typically verifies:

NDC matches label (strength and total volume).
Container integrity testing in shipping and receiving SOP.
Stability data for KCl in D5W under storage conditions.
Recall history and lot traceability capability.
Supply continuity: lead time and allocation policies during shortages.

Key takeaways

KCl 20 mEq in Dextrose 5% IV plastic is sourced primarily as a finished labeled product by an MAH tied to an NDC, then distributed via hospital wholesalers and GPO contract channels.
“Supplier” should mean the NDC/label MAH and their contract distributor, not merely a plastic bag manufacturer or generic compounding provider.
For reliable procurement, lock on NDC + container size + plastic bag type and qualify suppliers on traceability, stability/compatibility, and supply continuity.

FAQs

1) What is the correct way to request “KCl 20 mEq in D5W 5%” from a distributor?

Request by NDC and total bag volume (not by a partial description) and confirm “plastic container” on the order form.

2) Are there different container sizes for the same potassium chloride in dextrose 5% presentation?

Yes. The “20 mEq” label can map to different bag volumes depending on formulation, so the package size must match.

3) Can pharmacies compound this instead of buying premix?

Yes, through sterile compounding/admixture programs, but readiness depends on facility capability and whether pre-mix availability is sufficient.

4) What should clinicians verify before administration?

Verify the label strength (mEq), dextrose concentration (D5W), and bag volume, then confirm patient-specific potassium dosing.

5) What drives shortages for this IV category?

Typically manufacturing capacity constraints for IV bags/sterile solutions, KCl raw material supply, and distributor allocation of the specific NDC presentation.

References

FDA. Orange Book (NDC-linked product information). U.S. Food and Drug Administration.
USP. Pharmaceutical Compounding-Sterile Preparations <797>. United States Pharmacopeia.
FDA. Drug Shortages. U.S. Food and Drug Administration.

Suppliers and packagers for POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER